Shailendra K Saxena

This inventor holds 15 USPTO granted patents and 4 published patent applications. Top assignees: Alfacell Corporation, Tamir Biotechnology, Inc.. Active years: 2001-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shailendra K Saxena. Retrieved from https://idiyas.com/inventor/shailendra-k-saxena

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 4)

% Patents Active = 93.3

Average Co-Inventor Count = 1.1

ph-index = 4

Forward Citations = 62(Granted Patents)

Location History:

West Orange, NJ (US) (2001 - 2009)
Monroe Township, NJ (US) (2009 - 2014)

Company Filing History:

Tamir Biotechnology, Inc.

patents

Years Active: 2001-2014

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8808690 - Methods of treating infections originating from viruses in the herpesviridae family (2014-08-19),

2. 8663964 - Methods of treating human papillomavirus (2014-03-04),

3. 8518399 - Methods of treating infections originating from viruses in the herpesviridae family (2013-08-27),

4. 7763449 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an N-terminal leader sequence that is at least one residue long (2010-07-27),

5. 7585655 - Nucleic acid encoding a fusion protein incorporating a cysteinized ribonuclease (2009-09-08),

6. 7585654 - Nucleic acid encoding cysteinized ribonuclease to which a targeting moiety can be conjugated (2009-09-08),

7. 7556953 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an N-terminal leader sequence (2009-07-07),

8. 7556952 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of a known amino acid sequence and an initial N-terminal residue (2009-07-07),

9. 7556951 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an n-terminal leader sequence that is at least one residue long (2009-07-07),

10. 7473542 - Cysteinized ribonuclease and targeting moiety conjugated thereto (2009-01-06),

11. 7442536 - Cysteinized ribonuclease and targeting moiety conjugated thereto (2008-10-28),

12. 7442535 - Fusion protein incorporating a cysteinized ribonuclease (2008-10-28),

13. 7229824 - Ribonucleases and methods of making them recombinantly (2007-06-12),

14. 6423515 - Methods of making nucleic acids encoding ribonucleases (2002-07-23),

15. 6175003 - Nucleic acids encoding ribonucleases and methods of making them (2001-01-16),

Title: Inventor Shailendra K Saxena: A Pioneer in Antiviral Treatments

Introduction

Shailendra K Saxena, based in Monroe Township, NJ, is an accomplished inventor holding a remarkable portfolio of 15 patents. His work primarily revolves around the development of innovative antiviral treatments, addressing critical infections caused by various viruses.

Latest Patents

Among his most recent patents, Saxena has contributed significantly to methods of treating infections originating from viruses in the herpesviridae family. He has explored the efficacy of three ribonucleases (RNases) — ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2 — which were tested against identified herpesviridae infections. Quantitative PCR assays have shown that, with some exceptions, these RNases exhibit antiviral activity against a multitude of viruses in this family. Additionally, Saxena has developed methods for treating human papillomavirus (HPV) infections. His research demonstrated that ranpirnase and the second embodiment from U.S. Pat. No. 5,728,805 display antiviral activity against type 11 HPV, as evidenced by QRT-PCR assays.

Career Highlights

Saxena's distinguished career includes contributions to notable organizations in the biotechnology sector. He has worked with Alfacell Corporation and Tamir Biotechnology, Inc., where he has played an instrumental role in advancing antiviral research and developing therapeutic solutions. His extensive experience has positioned him as a recognized figure in both the academic and industry circles regarding viral treatment innovations.

Collaborations

One of Saxena’s notable collaborations includes his work alongside Wojciech J Ardelt, with whom he has shared valuable insights and expertise in the field of antiviral research. This collaborative effort has further enhanced the scope and impact of his innovative work.

Conclusion

Shailendra K Saxena continues to make significant strides in the field of antiviral therapies through his innovative patents and collaborative efforts. His dedication to research and development in combating viral infections places him at the forefront of medical advancements, benefiting countless individuals worldwide.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

4 patents pending: